Filtra Consultants & Engineers Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 26, 2025, 7:35 pm

Competitors of Filtra Consultants & Engineers Ltd

All Competitor Stocks of Filtra Consultants & Engineers Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:04 am

Below is a detailed analysis of the quarterly data for Filtra Consultants & Engineers Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 43.52 Cr.. The value appears strong and on an upward trend. It has increased from 43.41 Cr. (Sep 2024) to 43.52 Cr., marking an increase of 0.11 Cr..
• For Expenses, as of Mar 2025, the value is 42.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.28 Cr. (Sep 2024) to 42.59 Cr., marking an increase of 2.31 Cr..
• For Operating Profit, as of Mar 2025, the value is 0.93 Cr.. The value appears to be declining and may need further review. It has decreased from 3.13 Cr. (Sep 2024) to 0.93 Cr., marking a decrease of 2.20 Cr..
• For OPM %, as of Mar 2025, the value is 2.14%. The value appears to be declining and may need further review. It has decreased from 7.21% (Sep 2024) to 2.14%, marking a decrease of 5.07%.
• For Other Income, as of Mar 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.25 Cr. (Sep 2024) to 0.12 Cr., marking a decrease of 0.13 Cr..
• For Interest, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.01 Cr..
• For Depreciation, as of Mar 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.11 Cr. (Sep 2024) to 0.12 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Mar 2025, the value is 0.89 Cr.. The value appears to be declining and may need further review. It has decreased from 3.24 Cr. (Sep 2024) to 0.89 Cr., marking a decrease of 2.35 Cr..
• For Tax %, as of Mar 2025, the value is 24.72%. The value appears to be improving (decreasing) as expected. It has decreased from 30.86% (Sep 2024) to 24.72%, marking a decrease of 6.14%.
• For Net Profit, as of Mar 2025, the value is 0.67 Cr.. The value appears to be declining and may need further review. It has decreased from 2.24 Cr. (Sep 2024) to 0.67 Cr., marking a decrease of 1.57 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.61. The value appears to be declining and may need further review. It has decreased from 2.04 (Sep 2024) to 0.61, marking a decrease of 1.43.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 3:21 am

Growth

Last Updated: September 5, 2025, 3:30 pm

Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Filtra Consultants & Engineers Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 22, the value is 3.59. This value is below the healthy minimum of 5. It has increased from 1.62 (Mar 21) to 3.59, marking an increase of 1.97.
• For Diluted EPS (Rs.), as of Mar 22, the value is 3.59. This value is below the healthy minimum of 5. It has increased from 1.62 (Mar 21) to 3.59, marking an increase of 1.97.
• For Cash EPS (Rs.), as of Mar 22, the value is 3.82. This value is within the healthy range. It has increased from 1.84 (Mar 21) to 3.82, marking an increase of 1.98.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 20.32. It has increased from 16.85 (Mar 21) to 20.32, marking an increase of 3.47.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 20.32. It has increased from 16.85 (Mar 21) to 20.32, marking an increase of 3.47.
• For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 91.37. It has increased from 70.24 (Mar 21) to 91.37, marking an increase of 21.13.
• For PBDIT / Share (Rs.), as of Mar 22, the value is 5.36. This value is within the healthy range. It has increased from 2.61 (Mar 21) to 5.36, marking an increase of 2.75.
• For PBIT / Share (Rs.), as of Mar 22, the value is 5.14. This value is within the healthy range. It has increased from 2.41 (Mar 21) to 5.14, marking an increase of 2.73.
• For PBT / Share (Rs.), as of Mar 22, the value is 5.02. This value is within the healthy range. It has increased from 2.33 (Mar 21) to 5.02, marking an increase of 2.69.
• For Net Profit / Share (Rs.), as of Mar 22, the value is 3.61. This value is within the healthy range. It has increased from 1.64 (Mar 21) to 3.61, marking an increase of 1.97.
• For NP After MI And SOA / Share (Rs.), as of Mar 22, the value is 3.59. This value is within the healthy range. It has increased from 1.62 (Mar 21) to 3.59, marking an increase of 1.97.
• For PBDIT Margin (%), as of Mar 22, the value is 5.86. This value is below the healthy minimum of 10. It has increased from 3.70 (Mar 21) to 5.86, marking an increase of 2.16.
• For PBIT Margin (%), as of Mar 22, the value is 5.63. This value is below the healthy minimum of 10. It has increased from 3.42 (Mar 21) to 5.63, marking an increase of 2.21.
• For PBT Margin (%), as of Mar 22, the value is 5.49. This value is below the healthy minimum of 10. It has increased from 3.32 (Mar 21) to 5.49, marking an increase of 2.17.
• For Net Profit Margin (%), as of Mar 22, the value is 3.94. This value is below the healthy minimum of 5. It has increased from 2.33 (Mar 21) to 3.94, marking an increase of 1.61.
• For NP After MI And SOA Margin (%), as of Mar 22, the value is 3.92. This value is below the healthy minimum of 8. It has increased from 2.30 (Mar 21) to 3.92, marking an increase of 1.62.
• For Return on Networth / Equity (%), as of Mar 22, the value is 17.64. This value is within the healthy range. It has increased from 9.65 (Mar 21) to 17.64, marking an increase of 7.99.
• For Return on Capital Employeed (%), as of Mar 22, the value is 24.44. This value is within the healthy range. It has increased from 13.67 (Mar 21) to 24.44, marking an increase of 10.77.
• For Return On Assets (%), as of Mar 22, the value is 9.49. This value is within the healthy range. It has increased from 5.04 (Mar 21) to 9.49, marking an increase of 4.45.
• For Long Term Debt / Equity (X), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 22, the value is 0.00. This value is within the healthy range. It has decreased from 0.01 (Mar 21) to 0.00, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 22, the value is 2.57. It has increased from 2.27 (Mar 21) to 2.57, marking an increase of 0.30.
• For Current Ratio (X), as of Mar 22, the value is 1.98. This value is within the healthy range. It has increased from 1.89 (Mar 21) to 1.98, marking an increase of 0.09.
• For Quick Ratio (X), as of Mar 22, the value is 0.87. This value is below the healthy minimum of 1. It has increased from 0.86 (Mar 21) to 0.87, marking an increase of 0.01.
• For Dividend Payout Ratio (NP) (%), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 22, the value is 62.90. This value is within the healthy range. It has increased from 35.27 (Mar 21) to 62.90, marking an increase of 27.63.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 43.78. This value is within the healthy range. It has increased from 23.19 (Mar 21) to 43.78, marking an increase of 20.59.
• For Enterprise Value (Cr.), as of Mar 22, the value is 10.74. It has increased from 6.35 (Mar 21) to 10.74, marking an increase of 4.39.
• For EV / Net Operating Revenue (X), as of Mar 22, the value is 0.14. This value is below the healthy minimum of 1. It has increased from 0.10 (Mar 21) to 0.14, marking an increase of 0.04.
• For EV / EBITDA (X), as of Mar 22, the value is 2.43. This value is below the healthy minimum of 5. It has decreased from 2.96 (Mar 21) to 2.43, marking a decrease of 0.53.
• For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.11 (Mar 21) to 0.16, marking an increase of 0.05.
• For Retention Ratios (%), as of Mar 22, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 21) which recorded 0.00.
• For Price / BV (X), as of Mar 22, the value is 0.72. This value is below the healthy minimum of 1. It has increased from 0.49 (Mar 21) to 0.72, marking an increase of 0.23.
• For Price / Net Operating Revenue (X), as of Mar 22, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.11 (Mar 21) to 0.16, marking an increase of 0.05.
• For EarningsYield, as of Mar 22, the value is 0.24. This value is below the healthy minimum of 5. It has increased from 0.19 (Mar 21) to 0.24, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness